STOCK TITAN

[8-K] NeuroBo Pharmaceuticals, Inc. Common Stock Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Streamline Health Solutions, Inc. (Nasdaq: STRM) has filed a preliminary Schedule 14A seeking stockholder approval for its $5.34-per-share all-cash merger with Mist Holding Co., the parent of MDaudit. At closing, Merger Sub will merge into Streamline, which will become a wholly-owned subsidiary of MDaudit and cease to be publicly traded.

Key economic terms

  • Cash consideration of $5.34 per share, representing a 138 % premium to the 5/28/25 close and 117 % to the 30-day VWAP.
  • No financing contingency; Parent states it has sufficient cash on hand to fund the deal and related costs.
  • Options and warrants with exercise prices below $5.34 will be cashed-out; all currently outstanding options and warrants are “out-of-the-money” and will be cancelled for no consideration.
  • Termination fee payable by Streamline to Parent is $950 K; no reverse termination fee disclosed.

Governance & process

  • The Streamline Board unanimously approved the merger, deemed it fair, and recommends voting “FOR” all proposals.
  • Cain Brothers rendered a fairness opinion to the Board on 5/28/25.
  • Certain directors and officers entered into Voting & Support Agreements, committing their shares to support the transaction (exact percentage not yet specified).
  • Completion requires the affirmative vote of at least 66 2/3 % of outstanding shares. Failure to vote counts as an “AGAINST.”

Timeline & conditions

  • Special Meeting will be held virtually on a date to be set; record date also to be set.
  • Expected closing is Q3 2025, subject to stockholder approval and customary conditions (no financing or regulatory conditions highlighted).
  • Outside date for termination is 12/31/25.

Post-closing the STRM shares will be delisted from Nasdaq and deregistered under the Exchange Act. Stockholders who properly perfect appraisal rights under Delaware law may seek a court-determined “fair value” instead of the $5.34 cash payment.

Streamline Health Solutions, Inc. (Nasdaq: STRM) ha presentato un preliminare Schedule 14A per ottenere l'approvazione degli azionisti riguardo alla sua fusione totalmente in contanti a $5,34 per azione con Mist Holding Co., la società madre di MDaudit. Alla chiusura, Merger Sub si fonderà in Streamline, che diventerà una controllata interamente posseduta da MDaudit e cesserà di essere quotata in borsa.

Termini economici principali

  • Considerazione in contanti di $5,34 per azione, che rappresenta un premio del 138% rispetto alla chiusura del 28/05/25 e del 117% rispetto alla media ponderata del prezzo degli ultimi 30 giorni (VWAP).
  • Nessuna condizione di finanziamento; la società madre dichiara di avere liquidità sufficiente per finanziare l’operazione e i costi correlati.
  • Opzioni e warrant con prezzo di esercizio inferiore a $5,34 saranno liquidati in contanti; tutte le opzioni e i warrant attualmente in circolazione sono “out-of-the-money” e saranno cancellati senza alcun compenso.
  • La commissione di risoluzione pagabile da Streamline alla società madre è di $950.000; non è stata prevista alcuna commissione di risoluzione inversa.

Governance e processo

  • Il Consiglio di Amministrazione di Streamline ha approvato all'unanimità la fusione, ritenendola equa, e raccomanda di votare “A FAVORE” tutte le proposte.
  • Cain Brothers ha fornito un parere di equità al Consiglio il 28/05/25.
  • Alcuni amministratori e dirigenti hanno sottoscritto Accordi di Voto e Supporto, impegnando le loro azioni a sostenere la transazione (percentuale esatta non ancora specificata).
  • Il completamento richiede il voto favorevole di almeno il 66 2/3% delle azioni in circolazione. L’assenza di voto sarà considerata come voto “CONTRARIO”.

Tempistiche e condizioni

  • La riunione speciale si terrà virtualmente in data da definire; sarà anche stabilita la data di registrazione.
  • La chiusura è prevista per il terzo trimestre 2025, subordinata all’approvazione degli azionisti e alle condizioni consuete (non sono evidenziate condizioni di finanziamento o regolamentari).
  • La data limite per la risoluzione è il 31/12/25.

Dopo la chiusura, le azioni STRM saranno cancellate dalla quotazione Nasdaq e deregistrate ai sensi dell’Exchange Act. Gli azionisti che esercitano correttamente i diritti di valutazione secondo la legge del Delaware potranno richiedere un valore “equo” determinato dal tribunale invece del pagamento in contanti di $5,34.

Streamline Health Solutions, Inc. (Nasdaq: STRM) ha presentado un Schedule 14A preliminar solicitando la aprobación de los accionistas para su fusión completamente en efectivo a $5.34 por acción con Mist Holding Co., la matriz de MDaudit. Al cierre, Merger Sub se fusionará con Streamline, que se convertirá en una subsidiaria de propiedad total de MDaudit y dejará de cotizar públicamente.

Términos económicos clave

  • Consideración en efectivo de $5.34 por acción, representando una prima del 138% sobre el cierre del 28/05/25 y un 117% sobre el VWAP de 30 días.
  • No hay contingencia de financiamiento; la matriz declara tener efectivo suficiente para financiar el acuerdo y los costos relacionados.
  • Las opciones y warrants con precios de ejercicio por debajo de $5.34 serán liquidados en efectivo; todas las opciones y warrants actualmente en circulación están “out-of-the-money” y serán cancelados sin compensación.
  • La tarifa de terminación pagadera por Streamline a la matriz es de $950,000; no se ha divulgado tarifa de terminación inversa.

Gobernanza y proceso

  • La Junta Directiva de Streamline aprobó unánimemente la fusión, la consideró justa y recomienda votar “A FAVOR” de todas las propuestas.
  • Cain Brothers emitió una opinión de equidad a la Junta el 28/05/25.
  • Ciertos directores y funcionarios firmaron Acuerdos de Voto y Apoyo, comprometiendo sus acciones para apoyar la transacción (porcentaje exacto aún no especificado).
  • La finalización requiere el voto afirmativo de al menos el 66 2/3% de las acciones en circulación. La falta de voto se contará como un voto “EN CONTRA”.

Cronograma y condiciones

  • La reunión especial se realizará virtualmente en una fecha por determinar; también se establecerá la fecha de registro.
  • El cierre esperado es en el tercer trimestre de 2025, sujeto a la aprobación de los accionistas y condiciones habituales (no se destacan condiciones de financiamiento o regulatorias).
  • La fecha límite para la terminación es el 31/12/25.

Después del cierre, las acciones de STRM serán retiradas de Nasdaq y dadas de baja bajo la Exchange Act. Los accionistas que perfeccionen correctamente sus derechos de tasación bajo la ley de Delaware pueden buscar un “valor justo” determinado por un tribunal en lugar del pago en efectivo de $5.34.

Streamline Health Solutions, Inc. (Nasdaq: STRM)는 MDaudit의 모회사인 Mist Holding Co.와의 주당 $5.34 전액 현금 합병에 대해 주주 승인을 요청하는 예비 Schedule 14A를 제출했습니다. 거래 종료 시 Merger Sub는 Streamline과 합병되며, Streamline은 MDaudit의 완전 자회사가 되어 상장 폐지됩니다.

주요 경제 조건

  • 주당 $5.34의 현금 대가로, 2025년 5월 28일 종가 대비 138% 프리미엄, 30일 VWAP 대비 117% 프리미엄을 의미합니다.
  • 자금 조달 조건 없음; 모회사는 거래 및 관련 비용을 충당할 충분한 현금 보유를 명시했습니다.
  • 행사가가 $5.34 미만인 옵션과 워런트는 현금으로 정산되며, 현재 발행된 모든 옵션과 워런트는 “돈 밖” 상태로 보상 없이 취소됩니다.
  • Streamline이 모회사에 지급할 해지 수수료는 $95만이며, 역해지 수수료는 공개되지 않았습니다.

거버넌스 및 절차

  • Streamline 이사회는 만장일치로 합병을 승인하고 공정하다고 판단했으며 모든 안건에 대해 “찬성” 투표를 권고합니다.
  • Cain Brothers는 2025년 5월 28일 이사회에 공정성 의견을 제공했습니다.
  • 일부 이사 및 임원들은 거래 지지를 약속하는 투표 및 지원 계약을 체결했으며, 정확한 지분 비율은 아직 공개되지 않았습니다.
  • 완료를 위해서는 발행 주식의 최소 66 2/3% 찬성 투표가 필요하며, 투표하지 않는 경우 “반대”로 간주됩니다.

일정 및 조건

  • 특별 주주총회는 추후 지정될 날짜에 가상으로 개최되며, 기준일도 설정됩니다.
  • 거래 종료는 주주 승인 및 일반적인 조건 충족을 전제로 2025년 3분기로 예상됩니다 (자금 조달 또는 규제 조건은 특별히 언급되지 않음).
  • 해지 최종 기한은 2025년 12월 31일입니다.

종료 후 STRM 주식은 Nasdaq에서 상장 폐지되고 Exchange Act에 따라 등록 해제됩니다. 델라웨어 법에 따라 적절히 평가권을 행사한 주주는 $5.34 현금 지급 대신 법원이 결정하는 “공정 가치”를 청구할 수 있습니다.

Streamline Health Solutions, Inc. (Nasdaq : STRM) a déposé un Schedule 14A préliminaire sollicitant l'approbation des actionnaires pour sa fusion entièrement en numéraire à 5,34 $ par action avec Mist Holding Co., la société mère de MDaudit. À la clôture, Merger Sub fusionnera avec Streamline, qui deviendra une filiale en propriété exclusive de MDaudit et cessera d'être cotée en bourse.

Principaux termes économiques

  • Contrepartie en numéraire de 5,34 $ par action, représentant une prime de 138 % par rapport au cours de clôture du 28/05/25 et de 117 % par rapport au VWAP sur 30 jours.
  • Aucune condition de financement ; la société mère déclare disposer de liquidités suffisantes pour financer l'opération et les coûts associés.
  • Les options et bons de souscription avec un prix d'exercice inférieur à 5,34 $ seront rachetés en numéraire ; toutes les options et bons actuellement en circulation sont « hors du cours » et seront annulés sans contrepartie.
  • Les frais de résiliation payables par Streamline à la société mère s'élèvent à 950 000 $ ; aucun frais de résiliation inversé n'a été divulgué.

Gouvernance et processus

  • Le conseil d'administration de Streamline a approuvé à l'unanimité la fusion, l'a jugée équitable et recommande de voter « POUR » toutes les propositions.
  • Cain Brothers a rendu un avis d'équité au conseil le 28/05/25.
  • Certains administrateurs et dirigeants ont conclu des accords de vote et de soutien, engageant leurs actions à soutenir la transaction (le pourcentage exact n'a pas encore été précisé).
  • La réalisation nécessite le vote affirmatif d'au moins 66 2/3 % des actions en circulation. L'absence de vote sera comptabilisée comme un vote « CONTRE ».

Calendrier et conditions

  • Une assemblée générale spéciale se tiendra virtuellement à une date à déterminer ; la date de référence sera également fixée.
  • La clôture est prévue au 3e trimestre 2025, sous réserve de l'approbation des actionnaires et des conditions habituelles (aucune condition de financement ou réglementaire mise en avant).
  • La date limite de résiliation est le 31/12/25.

Après la clôture, les actions STRM seront radiées du Nasdaq et désenregistrées conformément à la Exchange Act. Les actionnaires qui exercent correctement leurs droits d'évaluation en vertu de la loi du Delaware peuvent demander une « juste valeur » déterminée par un tribunal au lieu du paiement en numéraire de 5,34 $.

Streamline Health Solutions, Inc. (Nasdaq: STRM) hat einen vorläufigen Schedule 14A eingereicht, um die Zustimmung der Aktionäre zu seiner vollständigen Barfusion zu $5,34 je Aktie mit Mist Holding Co., der Muttergesellschaft von MDaudit, einzuholen. Zum Abschluss wird Merger Sub mit Streamline verschmolzen, das dann eine hundertprozentige Tochtergesellschaft von MDaudit wird und nicht mehr börsennotiert ist.

Wesentliche wirtschaftliche Bedingungen

  • Bargeldzahlung von $5,34 je Aktie, was eine Prämie von 138% gegenüber dem Schlusskurs vom 28.05.25 und 117% gegenüber dem 30-Tage VWAP darstellt.
  • Keine Finanzierungsbedingung; die Muttergesellschaft gibt an, über ausreichende liquide Mittel zur Finanzierung des Geschäfts und der damit verbundenen Kosten zu verfügen.
  • Optionen und Warrants mit Ausübungspreisen unter $5,34 werden ausgezahlt; alle derzeit ausstehenden Optionen und Warrants sind „out-of-the-money“ und werden ohne Gegenleistung storniert.
  • Die von Streamline an die Muttergesellschaft zu zahlende Kündigungsgebühr beträgt $950.000; eine umgekehrte Kündigungsgebühr wurde nicht bekannt gegeben.

Governance & Prozess

  • Der Streamline-Vorstand hat die Fusion einstimmig genehmigt, sie als fair eingestuft und empfiehlt, allen Vorschlägen „ZUZUSTIMMEN“.
  • Cain Brothers erteilte dem Vorstand am 28.05.25 eine Fairness-Bewertung.
  • Bestimmte Direktoren und Führungskräfte haben Abstimmungs- und Unterstützungsvereinbarungen unterzeichnet, mit denen sie ihre Aktien zur Unterstützung der Transaktion verpflichten (genauer Prozentsatz noch nicht angegeben).
  • Der Abschluss erfordert eine Zustimmung von mindestens 66 2/3% der ausstehenden Aktien. Keine Stimmabgabe wird als „GEGEN“ gewertet.

Zeitplan & Bedingungen

  • Die außerordentliche Hauptversammlung wird virtuell an einem noch festzulegenden Datum abgehalten; auch der Stichtag wird noch bestimmt.
  • Der erwartete Abschluss ist für das 3. Quartal 2025 geplant, vorbehaltlich der Zustimmung der Aktionäre und üblicher Bedingungen (keine Finanzierungs- oder regulatorischen Bedingungen hervorgehoben).
  • Die Außenfrist für die Beendigung ist der 31.12.25.

Nach dem Abschluss werden die STRM-Aktien von Nasdaq delistet und gemäß dem Exchange Act deregistriert. Aktionäre, die ihre Bewertungsrechte nach dem Delaware-Recht ordnungsgemäß ausüben, können einen gerichtlich festgelegten „fairen Wert“ anstelle der Barzahlung von $5,34 verlangen.

Positive
  • 138 % cash premium to the unaffected share price provides immediate, above-market value to shareholders.
  • No financing contingency; Parent has sufficient cash on hand, boosting deal certainty.
  • Board unanimously supports the merger and obtained an independent fairness opinion.
  • Modest $950 K termination fee preserves the possibility of a superior proposal.
  • Support Agreements with certain insiders align management interests with transaction completion.
Negative
  • Super-majority vote (66 2/3 %) creates meaningful closing risk; abstentions count as ‘AGAINST.’
  • No-solicitation covenant restricts Streamline from actively seeking higher bids.
  • Failure to vote by retail shareholders could derail the deal despite board backing.
  • Options and warrants are out-of-the-money and will be cancelled, potentially dissatisfying some holders.
  • Termination outside date of 12/31/25 could push closing into 2026 if delays occur.

Insights

TL;DR Cash deal offers 138 % premium, no financing risk; high approval threshold is main hurdle.

From an M&A standpoint this transaction is straight‐forward and highly favorable to public holders. The $5.34 price implies an enterprise value well above Streamline’s unaffected market capitalization and is entirely in cash, eliminating execution risk tied to equity valuations. Importantly, Parent has certified adequate funds, so there is no financing condition or reverse termination fee. The termination fee of $950 K (≈1 % of equity value) is modest and unlikely to deter a superior bid should one emerge. Support Agreements from insiders further de-risk closing, though the exact ownership percentage remains undisclosed. Overall, the proposal delivers immediate, certain value and aligns with best-practice processes (fairness opinion, fiduciary out clauses). Key watch-item is the super-majority vote requirement: non-voting shares count as ‘AGAINST,’ making solicitation critical.

TL;DR Premium attractive but super-majority vote, modest break-fee and board lock-up temper certainty.

For portfolio holders, the 138 % premium crystallizes considerable upside versus pre-deal prices. However, approval demands 66 2/3 % of all shares outstanding, not just those present, raising the possibility of failure if retail investors are apathetic. The board’s no-solicitation covenant plus low break-fee could still allow topping offers, yet timing is tight under the 12/31/25 outside date. Delisting eliminates future upside participation in Streamline’s turnaround but guarantees liquidity now. Risk-reward skews positive, but I would monitor vote tallies closely and maintain a modest discount to the $5.34 consideration when pricing the shares until proxy results firm up.

Streamline Health Solutions, Inc. (Nasdaq: STRM) ha presentato un preliminare Schedule 14A per ottenere l'approvazione degli azionisti riguardo alla sua fusione totalmente in contanti a $5,34 per azione con Mist Holding Co., la società madre di MDaudit. Alla chiusura, Merger Sub si fonderà in Streamline, che diventerà una controllata interamente posseduta da MDaudit e cesserà di essere quotata in borsa.

Termini economici principali

  • Considerazione in contanti di $5,34 per azione, che rappresenta un premio del 138% rispetto alla chiusura del 28/05/25 e del 117% rispetto alla media ponderata del prezzo degli ultimi 30 giorni (VWAP).
  • Nessuna condizione di finanziamento; la società madre dichiara di avere liquidità sufficiente per finanziare l’operazione e i costi correlati.
  • Opzioni e warrant con prezzo di esercizio inferiore a $5,34 saranno liquidati in contanti; tutte le opzioni e i warrant attualmente in circolazione sono “out-of-the-money” e saranno cancellati senza alcun compenso.
  • La commissione di risoluzione pagabile da Streamline alla società madre è di $950.000; non è stata prevista alcuna commissione di risoluzione inversa.

Governance e processo

  • Il Consiglio di Amministrazione di Streamline ha approvato all'unanimità la fusione, ritenendola equa, e raccomanda di votare “A FAVORE” tutte le proposte.
  • Cain Brothers ha fornito un parere di equità al Consiglio il 28/05/25.
  • Alcuni amministratori e dirigenti hanno sottoscritto Accordi di Voto e Supporto, impegnando le loro azioni a sostenere la transazione (percentuale esatta non ancora specificata).
  • Il completamento richiede il voto favorevole di almeno il 66 2/3% delle azioni in circolazione. L’assenza di voto sarà considerata come voto “CONTRARIO”.

Tempistiche e condizioni

  • La riunione speciale si terrà virtualmente in data da definire; sarà anche stabilita la data di registrazione.
  • La chiusura è prevista per il terzo trimestre 2025, subordinata all’approvazione degli azionisti e alle condizioni consuete (non sono evidenziate condizioni di finanziamento o regolamentari).
  • La data limite per la risoluzione è il 31/12/25.

Dopo la chiusura, le azioni STRM saranno cancellate dalla quotazione Nasdaq e deregistrate ai sensi dell’Exchange Act. Gli azionisti che esercitano correttamente i diritti di valutazione secondo la legge del Delaware potranno richiedere un valore “equo” determinato dal tribunale invece del pagamento in contanti di $5,34.

Streamline Health Solutions, Inc. (Nasdaq: STRM) ha presentado un Schedule 14A preliminar solicitando la aprobación de los accionistas para su fusión completamente en efectivo a $5.34 por acción con Mist Holding Co., la matriz de MDaudit. Al cierre, Merger Sub se fusionará con Streamline, que se convertirá en una subsidiaria de propiedad total de MDaudit y dejará de cotizar públicamente.

Términos económicos clave

  • Consideración en efectivo de $5.34 por acción, representando una prima del 138% sobre el cierre del 28/05/25 y un 117% sobre el VWAP de 30 días.
  • No hay contingencia de financiamiento; la matriz declara tener efectivo suficiente para financiar el acuerdo y los costos relacionados.
  • Las opciones y warrants con precios de ejercicio por debajo de $5.34 serán liquidados en efectivo; todas las opciones y warrants actualmente en circulación están “out-of-the-money” y serán cancelados sin compensación.
  • La tarifa de terminación pagadera por Streamline a la matriz es de $950,000; no se ha divulgado tarifa de terminación inversa.

Gobernanza y proceso

  • La Junta Directiva de Streamline aprobó unánimemente la fusión, la consideró justa y recomienda votar “A FAVOR” de todas las propuestas.
  • Cain Brothers emitió una opinión de equidad a la Junta el 28/05/25.
  • Ciertos directores y funcionarios firmaron Acuerdos de Voto y Apoyo, comprometiendo sus acciones para apoyar la transacción (porcentaje exacto aún no especificado).
  • La finalización requiere el voto afirmativo de al menos el 66 2/3% de las acciones en circulación. La falta de voto se contará como un voto “EN CONTRA”.

Cronograma y condiciones

  • La reunión especial se realizará virtualmente en una fecha por determinar; también se establecerá la fecha de registro.
  • El cierre esperado es en el tercer trimestre de 2025, sujeto a la aprobación de los accionistas y condiciones habituales (no se destacan condiciones de financiamiento o regulatorias).
  • La fecha límite para la terminación es el 31/12/25.

Después del cierre, las acciones de STRM serán retiradas de Nasdaq y dadas de baja bajo la Exchange Act. Los accionistas que perfeccionen correctamente sus derechos de tasación bajo la ley de Delaware pueden buscar un “valor justo” determinado por un tribunal en lugar del pago en efectivo de $5.34.

Streamline Health Solutions, Inc. (Nasdaq: STRM)는 MDaudit의 모회사인 Mist Holding Co.와의 주당 $5.34 전액 현금 합병에 대해 주주 승인을 요청하는 예비 Schedule 14A를 제출했습니다. 거래 종료 시 Merger Sub는 Streamline과 합병되며, Streamline은 MDaudit의 완전 자회사가 되어 상장 폐지됩니다.

주요 경제 조건

  • 주당 $5.34의 현금 대가로, 2025년 5월 28일 종가 대비 138% 프리미엄, 30일 VWAP 대비 117% 프리미엄을 의미합니다.
  • 자금 조달 조건 없음; 모회사는 거래 및 관련 비용을 충당할 충분한 현금 보유를 명시했습니다.
  • 행사가가 $5.34 미만인 옵션과 워런트는 현금으로 정산되며, 현재 발행된 모든 옵션과 워런트는 “돈 밖” 상태로 보상 없이 취소됩니다.
  • Streamline이 모회사에 지급할 해지 수수료는 $95만이며, 역해지 수수료는 공개되지 않았습니다.

거버넌스 및 절차

  • Streamline 이사회는 만장일치로 합병을 승인하고 공정하다고 판단했으며 모든 안건에 대해 “찬성” 투표를 권고합니다.
  • Cain Brothers는 2025년 5월 28일 이사회에 공정성 의견을 제공했습니다.
  • 일부 이사 및 임원들은 거래 지지를 약속하는 투표 및 지원 계약을 체결했으며, 정확한 지분 비율은 아직 공개되지 않았습니다.
  • 완료를 위해서는 발행 주식의 최소 66 2/3% 찬성 투표가 필요하며, 투표하지 않는 경우 “반대”로 간주됩니다.

일정 및 조건

  • 특별 주주총회는 추후 지정될 날짜에 가상으로 개최되며, 기준일도 설정됩니다.
  • 거래 종료는 주주 승인 및 일반적인 조건 충족을 전제로 2025년 3분기로 예상됩니다 (자금 조달 또는 규제 조건은 특별히 언급되지 않음).
  • 해지 최종 기한은 2025년 12월 31일입니다.

종료 후 STRM 주식은 Nasdaq에서 상장 폐지되고 Exchange Act에 따라 등록 해제됩니다. 델라웨어 법에 따라 적절히 평가권을 행사한 주주는 $5.34 현금 지급 대신 법원이 결정하는 “공정 가치”를 청구할 수 있습니다.

Streamline Health Solutions, Inc. (Nasdaq : STRM) a déposé un Schedule 14A préliminaire sollicitant l'approbation des actionnaires pour sa fusion entièrement en numéraire à 5,34 $ par action avec Mist Holding Co., la société mère de MDaudit. À la clôture, Merger Sub fusionnera avec Streamline, qui deviendra une filiale en propriété exclusive de MDaudit et cessera d'être cotée en bourse.

Principaux termes économiques

  • Contrepartie en numéraire de 5,34 $ par action, représentant une prime de 138 % par rapport au cours de clôture du 28/05/25 et de 117 % par rapport au VWAP sur 30 jours.
  • Aucune condition de financement ; la société mère déclare disposer de liquidités suffisantes pour financer l'opération et les coûts associés.
  • Les options et bons de souscription avec un prix d'exercice inférieur à 5,34 $ seront rachetés en numéraire ; toutes les options et bons actuellement en circulation sont « hors du cours » et seront annulés sans contrepartie.
  • Les frais de résiliation payables par Streamline à la société mère s'élèvent à 950 000 $ ; aucun frais de résiliation inversé n'a été divulgué.

Gouvernance et processus

  • Le conseil d'administration de Streamline a approuvé à l'unanimité la fusion, l'a jugée équitable et recommande de voter « POUR » toutes les propositions.
  • Cain Brothers a rendu un avis d'équité au conseil le 28/05/25.
  • Certains administrateurs et dirigeants ont conclu des accords de vote et de soutien, engageant leurs actions à soutenir la transaction (le pourcentage exact n'a pas encore été précisé).
  • La réalisation nécessite le vote affirmatif d'au moins 66 2/3 % des actions en circulation. L'absence de vote sera comptabilisée comme un vote « CONTRE ».

Calendrier et conditions

  • Une assemblée générale spéciale se tiendra virtuellement à une date à déterminer ; la date de référence sera également fixée.
  • La clôture est prévue au 3e trimestre 2025, sous réserve de l'approbation des actionnaires et des conditions habituelles (aucune condition de financement ou réglementaire mise en avant).
  • La date limite de résiliation est le 31/12/25.

Après la clôture, les actions STRM seront radiées du Nasdaq et désenregistrées conformément à la Exchange Act. Les actionnaires qui exercent correctement leurs droits d'évaluation en vertu de la loi du Delaware peuvent demander une « juste valeur » déterminée par un tribunal au lieu du paiement en numéraire de 5,34 $.

Streamline Health Solutions, Inc. (Nasdaq: STRM) hat einen vorläufigen Schedule 14A eingereicht, um die Zustimmung der Aktionäre zu seiner vollständigen Barfusion zu $5,34 je Aktie mit Mist Holding Co., der Muttergesellschaft von MDaudit, einzuholen. Zum Abschluss wird Merger Sub mit Streamline verschmolzen, das dann eine hundertprozentige Tochtergesellschaft von MDaudit wird und nicht mehr börsennotiert ist.

Wesentliche wirtschaftliche Bedingungen

  • Bargeldzahlung von $5,34 je Aktie, was eine Prämie von 138% gegenüber dem Schlusskurs vom 28.05.25 und 117% gegenüber dem 30-Tage VWAP darstellt.
  • Keine Finanzierungsbedingung; die Muttergesellschaft gibt an, über ausreichende liquide Mittel zur Finanzierung des Geschäfts und der damit verbundenen Kosten zu verfügen.
  • Optionen und Warrants mit Ausübungspreisen unter $5,34 werden ausgezahlt; alle derzeit ausstehenden Optionen und Warrants sind „out-of-the-money“ und werden ohne Gegenleistung storniert.
  • Die von Streamline an die Muttergesellschaft zu zahlende Kündigungsgebühr beträgt $950.000; eine umgekehrte Kündigungsgebühr wurde nicht bekannt gegeben.

Governance & Prozess

  • Der Streamline-Vorstand hat die Fusion einstimmig genehmigt, sie als fair eingestuft und empfiehlt, allen Vorschlägen „ZUZUSTIMMEN“.
  • Cain Brothers erteilte dem Vorstand am 28.05.25 eine Fairness-Bewertung.
  • Bestimmte Direktoren und Führungskräfte haben Abstimmungs- und Unterstützungsvereinbarungen unterzeichnet, mit denen sie ihre Aktien zur Unterstützung der Transaktion verpflichten (genauer Prozentsatz noch nicht angegeben).
  • Der Abschluss erfordert eine Zustimmung von mindestens 66 2/3% der ausstehenden Aktien. Keine Stimmabgabe wird als „GEGEN“ gewertet.

Zeitplan & Bedingungen

  • Die außerordentliche Hauptversammlung wird virtuell an einem noch festzulegenden Datum abgehalten; auch der Stichtag wird noch bestimmt.
  • Der erwartete Abschluss ist für das 3. Quartal 2025 geplant, vorbehaltlich der Zustimmung der Aktionäre und üblicher Bedingungen (keine Finanzierungs- oder regulatorischen Bedingungen hervorgehoben).
  • Die Außenfrist für die Beendigung ist der 31.12.25.

Nach dem Abschluss werden die STRM-Aktien von Nasdaq delistet und gemäß dem Exchange Act deregistriert. Aktionäre, die ihre Bewertungsrechte nach dem Delaware-Recht ordnungsgemäß ausüben, können einen gerichtlich festgelegten „fairen Wert“ anstelle der Barzahlung von $5,34 verlangen.

0001638287false00016382872025-06-302025-06-30
UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549FORM 8-KCURRENT REPORTPursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934Date of Report (Date of earliest event reported): June 30, 2025GraphicMETAVIA INC.(Exact name of Registrant as Specified in Its Charter)
Delaware001-3780947-2389984
(State or other jurisdictionof incorporation)(CommissionFile Number)(IRS EmployerIdentification No.)
545 Concord Avenue, Suite 210Cambridge, Massachusetts 02138
(Address of principal executive offices)(Zip Code)
(857) 702-9600(Registrant’s telephone number, including area code)Not applicable(Former name or former address, if changed since last report)Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class    TradingSymbol(s)    Name of each exchange on which registered
Common Stock, par value $0.001 per share MTVA The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
Item 5.07.Submission of Matters to a Vote of Security Holders.On June 30, 2025, MetaVia Inc. (the “Company”) held a virtual annual meeting of stockholders (the “Annual Meeting”). The Company’s stockholders voted on six proposals at the Annual Meeting as set forth below, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on June 10, 2025. There were 15,364,255 shares of common stock, par value $0.001 per share (the “Common Stock”) present and entitled to vote at the Annual Meeting, online or by proxy, which constituted a quorum for the transaction of business. In deciding the proposals at the Annual Meeting, each share of Common Stock represented one vote.At the Annual Meeting, the Company’s stockholders voted on the following proposals:
1.To elect two Class III directors, each to serve a three-year term until the 2028 annual meeting of stockholders and until the election and qualification of such director’s successor, or such director’s earlier death, resignation, or removal (the “Class III Directors Proposal”);
2.To ratify the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025;
3.To approve (on an advisory basis) the compensation of the Company’s named executive officers;
4.To approve an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended, to effect a reverse split of the Company’s outstanding Common Stock at a ratio in the range of 1-for-5 to 1-for-30 to be determined at the discretion of the Company’s Board of Directors, whereby each outstanding 5 to 30 shares of Common Stock would be combined, converted and changed into one share of the Company’s Common Stock (the “Reverse Stock Split Proposal”);
5.to approve, pursuant to Nasdaq Listing Rule 5635(b), the issuance of shares of the Company’s Common Stock, in an amount equal to or in excess of 20% of the shares of Common Stock outstanding immediately prior to the issuance of 4,605,162 shares of Common Stock issuable upon the exercise of the Company’s pre-funded warrants, issued in a private placement to Dong-A Socio Holdings Co., Ltd., pursuant to a Securities Purchase Agreement, dated May 8, 2025, entered into by and among the Company and the purchasers named therein (the “Issuance Proposal”); and
6.To authorize one or more adjournments of the Annual Meeting to solicit additional proxies in the event there are insufficient votes to approve Proposal 5 described above (the “Adjournment Proposal”).
The voting results at the Annual Meeting are shown below:Proposal 1—The Class III Directors Proposal.
Class III Nominees    Votes For    Votes Withheld    
Mark A. Glickman  15,143,768220,487
Michael Salsbury  15,148,736215,519
​Mark A. Glickman and Michael Salsbury were elected as Class III directors to serve until the 2028 annual meeting of stockholders. There were no broker non-votes on this matter.Proposal 2—Ratification of the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
Votes For    Votes Against    Abstentions
15,200,51739,673124,065
​The stockholders ratified the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. There were no broker non-votes on this matter. Proposal 3—Approval (on an advisory basis) of the compensation of our named executive officers.
Votes For    Votes Against    Abstentions
15,128,18293,199142,874
The stockholders approved, on a non-binding advisory basis, the compensation paid by the Company to its named executive officers. There were no broker non-votes on this matter.
Proposal 4—The Reverse Stock Split Proposal.
Votes For    Votes Against    Abstentions
15,160,14382,570121,542
The stockholders approved the Reverse Stock Split Proposal. There were no broker non-votes on this matter.Proposal 5—The Issuance Proposal.
Votes For    Votes Against    Abstentions
5,643,79899,638141,474
The stockholders approved the Issuance Proposal. There were no broker non-votes on this matter.Proposal 6—The Adjournment Proposal.
Votes For    Votes Against    Abstentions
15,130,97291,911141,372
The stockholders approved the Adjournment Proposal. There were no broker non-votes on this matter.
SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    METAVIA INC.
Date: June 30, 2025By: /s/ Hyung Heon Kim
Hyung Heon Kim
President and Chief Executive Officer

FAQ

What premium does the $5.34 offer represent for STRM shareholders?

The cash price equals a 138 % premium to the 5/28/25 close and 117 % over the 30-day VWAP.

What vote is required for Streamline (STRM) to approve the merger?

At least 66 2/3 % of all outstanding common shares must vote "FOR" the Merger Proposal.

Is the transaction subject to financing or regulatory conditions?

Parent affirmed it has sufficient cash; the merger carries no financing condition. Only customary legal injunction conditions apply.

When is the Streamline merger expected to close?

Management targets Q3 2025, with an outside termination date of 12/31/25.

What happens to my STRM shares if the merger closes?

Each share converts into $5.34 cash; the stock will be delisted and deregistered.

Do shareholders have appraisal rights under Delaware law?

Yes. Holders who do not vote FOR the merger and follow Section 262 procedures may seek a court-determined fair value.
Neurobo Pharmaceuticals Inc

NASDAQ:NRBO

NRBO Rankings

NRBO Latest News

NRBO Stock Data

20.33M
3.00M
65.24%
12.71%
0.4%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE